Durability of immune responses to the BNT162b2 mRNA vaccine
M. Suthar, P. S Arunachalam, M. Hu, N. Reis, M. Trisal, O. Raeber, S. Chinthrajah, M. E. Davis-Gardner, K. Manning, P. Mudvari, S. Godbole, E. Boritz, A. R. Henry, D. Douek, K. Nadeau, , P. Halfmann
This study shows that antibody and T cell responses to the BNT162b2 vaccine wane significantly at 6 months, suggesting a potential need for a third booster dose.
bioRxiv · Sep 30, 2021Immunology